Potash Investment Thesis

Potash Investment Thesis-17
Another common mistake: “don’t rush into an investment and make sure you know what you’re getting into on multiple levels.” Mc Camant pointed out that investors need to be aware of the phases that most life sciences companies go through as they advance from initial drug testing to human clinical trials, to eventual commercialization.Timing it right can result in every investor’s dream of a 10 bagger.While the life sciences sector is not immune to the vagaries of stock markets and macroenomic trends such as inflation and economic growth, recent numbers show that it has done quite well in the face of some challenging economic headwinds.

Mc Camant believes that from an investor point of view, pharmaceutical companies carry the best chance of high returns considering their potential for developing cures for intractable diseases like cancer, Alzheimer’s disease and multiple sclerosis.

Companies that succeed in finding cures can develop drugs whose patient costs run up to $100,000 a year; while that is a heavy burden to pass onto a patient, it translates into huge profits for the corporations that manufacture such drugs.

Investors who get into these stocks early enough can see returns in excess of 10 times their original investment.

However, there are risks, an important one being side effects from drugs.

“It’s risk versus benefit or greed versus reward,” he said in an interview with Life Science Investing News.

“How much effect am I having on the patient versus the side effects?Mistime it and your gains could quickly turn to losses, especially if the company has poor testing data or runs afoul of the FDA, whose job is to protect the public.And like other sectors, it’s important to watch out for red flags such as overdilution, or what Mc Camant describes as “monsters,” such as Obamacare, which resulted in the whole sector trading off.For example, those associated with chemotherapy can make the treatment unworthy of the payoff.Mc Camant equates it to the stock market in terms of risk versus reward.“You’ve got to be able to interact with your own scientists, the FDA are very detailed and they also need to know and understand the science, and if you’re public you need to deal with Wall Street.You also need to potentially do partnerships with large and small companies.” Those that do well are the ones that best manage expectations, he noted.The baby boomers will continue spending on healthcare and healthcare products, even as budgets get crimped by entitlement reductions,” he noted.Small-pharma, cancer treatment are investment targets John Mc Camant is the editor of the Medical Technology Stock Letter, an established source for stock recommendations and news about medical technology companies.Over the years, as medical science and other technologies, like computing power, have advanced, the industry has morphed into a sector containing hundreds of companies, some of which have market capitalizations well over billion.With healthcare eating up an ever-greater proportion of government budgets — last year, health expenditures represented close to a quarter (23 percent) of government spending in the United States — and the western world’s reliance on pharmaceutical drugs unlikely to abate, investing in health-related companies is a solid investment strategy.


Comments Potash Investment Thesis

  • Intrepid Potash NYSEIPI reported earnings of $0.06 per share beating.

    Intrepid Potash NYSEIPI reported 12/31/2018 earnings this Morning, coming in at $0.06 per share, beating Wall Street’s estimates of $0.03 per Share. Revenue for the quarter came in at $34.90.…

  • Stephens Upgrades Intrepid On Rising Water, Potash Demand -

    Nearly a decade ago, Intrepid Potash, Inc. NYSE IPI traded close to $70. Steady corrosion has brought it to $4. Although not expected to scale its peaks any time soon, Intrepid may now boast.…

  • Potash – Investiv

    This article is going to elaborate on an investing thesis for potash producers. Current Situation. Two supply contracts, between the Belarusian Potash Corporation and two major Asian consumers, China and India, are very important for potash prices.…

  • Positive Signs for Potash - AOL Finance

    Potash appears to be in good shape in terms of the intangible assets ratio and tangible book value. You can never base an entire investment thesis on one or two metrics, but there are no yellow.…

  • Big potash says Jansen is mission 'impossible' for BHP

    An investment decision on the project is expected within 18 months and BHP signalled first production of potash, which is a crop nutrient typically used by farmers, could start within five years.…

  • Applied Investment Management AIM Program

    Investment of $2 B is required for each increase in metric ton of potash production. Also, with an average duration of 5-7 years for completion, potash expansion necessitates a considerable amount of time. Furthermore, world potash reserves are scarce, the Canpotex cartel along with…

  • Verde Potash Plc TSXNPK Stock Message Board - InvestorsHub

    That is the conclusion of a new report from Wellington West Capital Markets that suggests existing potash industry leaders who have benefited from market dominance in recent years, stand to lose the most if Brazil becomes potash self-sufficient and the next major independent exporter of this strategic resource.…

  • Andrea Rubakovic Will Pitfalls Create A Global Potash Shortage.

    The investment thesis a few years ago was that reaching these milestones could spark large investment by Indian, Chinese and Brazilians entities looking to secure fertilizer supplies.…

  • W Potash West NL PWN - The Digger

    Investment Thesis Potash West ASX PWN owns 100% of the Dandaragan Trough project covering very large greensand deposits quartz, apatite, glauconite that can be processed to produce a range of fertiliser and chemical products. A series of scoping level studies have been undertaken assessing development options.…

The Latest from srk-msk.ru ©